Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Hormone. CRCUM-Universite de Montreal, Montreal, Quebec, Canada



Survival: 15.8 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
Hormone
   
Drugs:
Country: Canada
   
City/State/Province: Montreal, Quebec
   
Hospital: CRCUM-Universite de Montreal
   
Journal: Link
   
Date: 9/2011

Description:
Patients:
This study involved men with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Patients were divided into two separate treatment groups. Group A consisted of 20 patients with a median age of 68 years, while group B had 22 patients with a median age of 61 years.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel, the steroid hormone prednisone, and the biologic therapy agent called custirsen. Custirsen is classified as an antisense oligonucleotide and stops the production of an anti-cell death protein (clusterin).

Patients in group B were treated with the chemotherapy agent mitoxantrone, the steroid hormone prednisone, and the biologic therapy agent called custirsen.

Toxicities:
The most severe toxicities in group A were of grade 4. Grade 3-4 adverse events included fatigue, lymphopenia, and infection.

There were two treatment-related deaths in group B due to infection and heart attack. Grade 3-4 lymphopenia, fatigue, and weakness were also reported.

Results:
The median overall survival rates for groups A and B were 15.8 and 11.5 months, respectively.

Support:
This study was partially supported by Sanofi Aventis Pharmaceuticals.

Correspondence: Dr. Fred Saad; email: fred.saad.chum@ssss.gouv.qc.ca

E-mail to a Friend Email Physician More Information